Tilray Medical Joins London Talks on Europe's Cannabis Regulation

Tilray Medical's European Regulatory Engagement

Tilray Medical attended policy discussions in London on May 26, 2026, addressing Europe's fragmented medical cannabis regulatory landscape. The pharmaceutical subsidiary operates EU-GMP-certified cultivation and manufacturing facilities in Portugal. Since 2021, it's expanded its European footprint significantly. Tilray Medical holds marketing authorizations for cannabis-based medicines in Germany, the United Kingdom, and Poland.

The London talks occurred as the European Commission evaluates proposals to harmonize medical cannabis access rules across the EU's 27 member states. Regulations vary widely. Germany permits medical cannabis prescriptions for any condition when conventional therapies fail, while France restricts cannabis-based medicines to a narrow list of conditions under an experimental framework that expires in March 2027.

Tilray Brands reported €17.3 million in European medical cannabis revenue for the quarter ended February 28, 2026, a 22% increase year-over-year, according to its March 2026 earnings filing. European operations include cultivation facilities in Portugal and distribution agreements with pharmacy networks in Germany, the UK, Poland, and Australia.

Europe's Fragmented Medical Cannabis Market

Twenty-two EU member states have enacted some form of medical cannabis access law, but regulatory inconsistency creates barriers for manufacturers and patients. Germany leads European medical cannabis consumption, with approximately 300,000 active prescriptions as of December 2025, according to the Federal Institute for Drugs and Medical Devices. The UK permits cannabis-based medicines under specialist prescription only. Italy operates a state-controlled cultivation and distribution system through its Military Chemical Pharmaceutical Plant in Florence.

In April 2026, the European Commission circulated its draft Medical Cannabis Framework Directive to member states, proposing standardized GMP requirements, mutual recognition of marketing authorizations, and harmonized prescription protocols. No formal publication date has been set. The draft directive remains under review.

Poland expanded its medical cannabis program in January 2026, removing the requirement for specialist physician approval and allowing general practitioners to prescribe cannabis-based medicines. That policy change increased prescription volume by 41% in the first quarter of 2026 compared to Q4 2025, according to Poland's Ministry of Health.

Industry Pressure for Harmonization

Pharmaceutical companies including Tilray Medical, Canopy Growth, and Jazz Pharmaceuticals have pushed the European Commission for unified regulatory standards since 2024. In February 2026, the European Industrial Hemp Association submitted a formal position paper calling for mutual recognition of GMP certifications and elimination of country-specific import licensing requirements.

Without harmonization, manufacturers must navigate 22 separate regulatory regimes. Marketing authorization applications in Germany require clinical trial data specific to the German patient population, while the UK accepts trial data from any jurisdiction with comparable regulatory standards. France's experimental framework prohibits flower products entirely, limiting access to oil extracts and oral capsules.

For context on the broader European regulatory environment, see the CannIntel topic hub on Europe Medical Cannabis Regulation.

In March 2026, the European Parliament's Committee on the Environment, Public Health and Food Safety held hearings on medical cannabis harmonization. No legislative proposal has advanced to a floor vote. Germany and the Netherlands support harmonization; France and Sweden oppose broader access frameworks, citing concerns about recreational diversion and insufficient long-term safety data.

What comes next? The European Commission's formal release of the Medical Cannabis Framework Directive, expected between June and September 2026. Until then, manufacturers operate in a patchwork system that limits patient access and complicates supply-chain logistics across borders.